
Evaluation of children with elevated creatinine in EK, PICU, NICU, Pediatric Wards



- Huber W, et al. Validation of RIFLE, AKIN, and a modified AKIN definition ("backward classification") of acute kidney injury in a general ICU: Analysis of a 1-year period. Medicine (Baltimore). 2018 Sep;97(38):e12465.
- 2. Akcan-Arikan A, et al. Modified RIFLE criteria in critically ill children with Acute Kidney Injury. Kidney Int. 2007; 71:1028-1035.
- 3. Katsoufis K, et al. Risk assessment of severe congenital anomalies of the kidney and urinary tract (CAKUT): A birth cohort. Frontiers in Pediatrics, 2019, 7:1-10.
- Stanski N, Menon S, Goldstein SL, Basu RK. Integration of urinary neutrophil-gelatinase-associated lipocalin with serum creatinine delineates acute kidney injury phenotypes in critically ill children. Journal of Critical Care, 2019, 53:1-7.
- 5. London AKI network National Institute for Clinical Excellence (NICE) Quality standard 2014 https://pathways.nice.org.uk/pathways/acute-kidney-injury

This clinical guideline is intended as an evidence-based guide for clinical care and not as a replacement for clinical decision making



New Pediatric Clinical Guideline Setup Checklist

Guideline Name: Acute Kidney Injury - AKI Goal of Clinical Guideline: uniform management – awareness, prevention and Rx

Does the proposed guideline meet the below four criteria?

	The intervention is a s	tructured multidisciplinary plan of c	care
--	-------------------------	---------------------------------------	------

- The intervention is used to translate guidelines or evidence into local structures
- The intervention details the steps in a course of treatment or care in a plan, pathway, algorithm, guideline, protocol or other 'inventory of actions' (i.e. the intervention had time-frames or criteria-based progression)
- The intervention aims to standardize care for a specific population

(Lawal et al. What is a clinical pathway? Refinement of an operational definition to identify clinical pathway studies for a Cochrane systematic Review. BMC Medicine (2016) 14:35)

CHECKLIST

Physician (or an alternate author) submitting the clinical guideline must be able (directly or through virtual meeting) to attend Clinical Guidelines Meeting	
All participants in the clinical guideline development should be listed and primary author identified	
Participants who are submitting clinical guideline should sign off and include the division chief(s) from all involved specialties (for purposes of disseminating to entire division)	
All clinical guidelines should include a disclaimer "this clinical guideline is intended as an evidence- based guide for clinical care and not as a replacement for clinical decision making"	
Clinical guideline authors should submit an estimated revision schedule, i.e. every 3 years.	
References must be included in the submission.	
Authors of the guideline must identify 1-2 quality metrics that can be measured to gauge impact on care awareness of AKI - place dx on problem list, and use of guideline	

Signature of Contributing Pathway Developers:

Dept. Name	MD Developer Name	Signature
Pediatric Nephrology	Alex Constantinescu, MD	Megazaut
Pediatric ER	Deanna Soloway, MD	platting
Pediatric ICU	Jason L Adler, MD	SA_
Neonatal ICU	Doron Kahn, MD	Dam Em
Pediatric Hospital Medicine	Angelique Martinez, MD	Anoti

Date Version 2.0 2.6.2020

Clinical Improvement Team Members

APPROVED BY

MANUAL/DEPARTMENT	
ORIGINATION DATE	
LAST DATE OF REVIEW OR REVISION	
REVIEWED BY	
APPROVAL BY	

REVIEW/REVISION SCHEDULE